Fairmount Funds Management, Director: Cogent Biosciences COGT Buy · Filed 25/07/14

Trade details

Type: Insider buy
Amount: $24,999,993
Shares · price: 2,777,777 sh · $9.00 a share
Held after: 9,003,418 sh
Stock: Cogent Biosciences COGT
Person: Fairmount Funds ManagementDirector
Trade date: 25/07/10
Filed: 25/07/14
Days to filing: 4 days

First buy in 2 years

Since the last buy: 2.1 years
Last buy: 23/06/09
Insiders buying this week: 1 insiders
Holding change: +44.6%

Cogent Biosciences trades, last 26 weeks

What else happened in Cogent Biosciences around then

Filed or reported within 30 days of the trade day · 25/06/10~25/08/09

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31